Jenny E. Blau

2.3k citations

39 papers · 1.5k indexed · 1 hit paper · h-index 15

Impact in

Endocrinology, Diabetes and Metabolism top 1%
- Diabetes Treatment and Management
- Diabetes Management and Research
Nephrology top 2%
- Parathyroid Disorders and Treatments

Papers in

Nephrology 7
- Parathyroid Disorders and Treatments 7
Endocrinology, Diabetes and Metabolism 11
- Diet, Metabolism, and Disease 4
- Diabetes Treatment and Management 4

Co-authors: Kristina I. Rother Simeon I. Taylor Michael T. Collins Sri Harsha Tella Allison C. Sylvetsky Mary Walter Viviana Bauman Amber L. Beitelshees
Journals: The Journal of Clinical Endocrinology & Metabolism (3 papers)Diabetes/Metabolism Research and Reviews (2 papers)The Lancet Diabetes & Endocrinology (2 papers)Reviews in Endocrine and Metabolic Disorders (2 papers)JCI Insight (2 papers)
Partner nations: United States Sweden United Kingdom

In The Last Decade

Jenny E. Blau

36 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

SGLT2 Inhibitors May Predispose to Ketoacidosis 2015 · 396 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 The Journal of Clinical Endocrinology & Metabolism

Peers

Countries citing papers authored by Jenny E. Blau

Since Specialization

Citations

This map shows the geographic impact of Jenny E. Blau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jenny E. Blau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jenny E. Blau more than expected).

Fields of papers citing papers by Jenny E. Blau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jenny E. Blau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jenny E. Blau. The network helps show where Jenny E. Blau may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jenny E. Blau, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jenny E. Blau Line = papers co-authored together Jenny E. Blau links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Genotype-phenotype correlation in multiple endocrine neoplasia type 1 JCI Insight ·F. Pérez-Carrillo, V.N. Krasnozhen, Jia Chang-sheng, James Welch, Lynn S. Bliss, Craig Cochran, Alfredo Valencia Toledo, Sheila Kumar, Stephen A. Wank, Sungyoung Auh, Lee S. Weinstein, William F. Simonds, Sunita Agarwal, Jenny E. Blau, Smita Jha	2025	0
2	Design and rationale for a global novel non-invasive screening observational study using genetics and non-invasive methodologies to identify at-risk MASLD participants: The ALIGN study Contemporary Clinical Trials Communications ·Samuel J. Daniels, Karin Nelander, John Eriksson, Lutz Jermutus, Jelena Saillard, 蓝伟珠, Federica Tavaglione, Marco Arrese, Alma Laura Ladrón de Guevara, Umberto Vespasiani‐Gentilucci, Naim Alkhouri, Jenny E. Blau	2025	0
3	Multidisciplinary considerations for implementing Bayesian borrowing in basket trials Drug Discovery Today ·Kristine Broglio, Jenny E. Blau, Elizabeth A. Pilling, James Wason	2024	0
4	Non‐invasive assessment of hepatic steatosis by ultrasound‐derived fat fraction in individuals at high‐risk for metabolic dysfunction‐associated steatotic liver disease Diabetes/Metabolism Research and Reviews ·Federica Tavaglione, Hasan Marwan Yahay Al Saleem, 任茹, Paolo Gallo, Irawaty Igirisa, Chaizada Yeskibayeva, Antonio De Vincentis, Andrea Palermo, Elliott J. Schuchardt, Giovanni Galati, Nicola Napoli, Samuel J. Daniels, Jenny E. Blau, Björn Carlsson, Yeganeh Manon Khazrai, Raffaele Antonelli Incalzi, Antonio Picardi, Umberto Vespasiani‐Gentilucci	2024	8
5	The greater impact of PNPLA3 polymorphism on liver‐related events in Japanese non‐alcoholic fatty liver disease patients: A multicentre cohort study Liver International ·Yuya Seko, Kanji Yamaguchi, Toshihide Shima, Michihiro Iwaki, Hirokazu Takahashi, Miwa Kawanaka, Saiyu Tanaka, Yasuhide Mitsumoto, Masato Yoneda, Atsushi Nakajima, Ola Fjellström, Jenny E. Blau, Björn Carlsson, Takeshi Okanoue, Yoshito Itoh	2023	21
6	Validity of Secretin Stimulation Testing on Proton Pump Inhibitor Therapy for Diagnosis of Zollinger-Ellison Syndrome The American Journal of Gastroenterology ·Ianoşi Sl, Jenny E. Blau, Craig Cochran, Sungyoung Auh, Lee S. Weinstein, Robert T. Jensen, Stephen A. Wank	2021	3
7	Familial Hyperparathyroidism Frontiers in Endocrinology ·Jenny E. Blau, William F. Simonds	2021	19
8	Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism Endocrine ·蘇丞映, Kilian Brown, Douglas Runkel, Г.Т. Абдрахманова, Mari Suzuki, Ricardo Correa, Jenny E. Blau, Andrew P. Demidowich, Constantine A. Stratakis, Ranganath Muniyappa	2021	9
9	Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia Journal of Bone and Mineral Research ·Iris R. Hartley, Rachel I. Gafni, Kelly L. Roszko, Karel Vermeyen, Luis F de Castro, 和彦野々村, Carlos R. Ferreira, William A. Gahl, Karel Pacák, Jenny E. Blau, Alison M. Boyce, Isidro B. Salusky, Michael T. Collins, Pablo Florenzano	2020	18
10	c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs Journal of Molecular Endocrinology ·Svetlana Kudinova, Sister Francis Dolores. Covella, Miron Milly, Lee S. Weinstein, Jaydira Del Rivero, Sunita Agarwal, Jenny E. Blau	2020	5
11	SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks The Lancet Diabetes & Endocrinology ·Simeon I. Taylor, Jenny E. Blau, Kristina I. Rother, Amber L. Beitelshees	2019	79
12	Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study JCI Insight ·Jenny E. Blau, Viviana Bauman, S.M.C.T.Siriwardhana, Paolo Piaggi, Mary Walter, Elizabeth C. Wright, Shanna Bernstein, Amber B. Courville, Michael T. Collins, Kristina I. Rother, Simeon I. Taylor	2018	118
13	Adverse effects of SGLT2 inhibitors on bone health Nature Reviews Nephrology ·Jenny E. Blau, Simeon I. Taylor	2018	53
14	High prevalence of chronic kidney disease in patients with multiple endocrine neoplasia type 1 and improved kidney function after parathyroidectomy Surgery ·C. Lindley, Jonathan Zagzag, Dhaval Patel, Lee S. Weinstein, William F. Simonds, Jenny E. Blau, Stephen J. Marx, Electron Kebebew, Nancy D. Perrier, Naris Nilubol	2018	5
15	Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data Diabetes/Metabolism Research and Reviews ·Jenny E. Blau, Sri Harsha Tella, Simeon I. Taylor, Kristina I. Rother	2017	169
16	Understanding the metabolic and health effects of low-calorie sweeteners: methodological considerations and implications for future research Reviews in Endocrine and Metabolic Disorders ·Allison C. Sylvetsky, Jenny E. Blau, Kristina I. Rother	2016	31
17	18F-NaF and 18F-FDG PET/CT in Gorham-Stout Disease Clinical Nuclear Medicine ·Georgios Z. Papadakis, Corina Millo, Ulaş Bağcı, Jenny E. Blau, Michael T. Collins	2016	13
18	Nonnutritive Sweeteners in Breast Milk Journal of Toxicology and Environmental Health ·Allison C. Sylvetsky, 郑朝卿, Viviana Bauman, Jenny E. Blau, H. Martin Garraffo, Peter J. Walter, Kristina I. Rother	2015	66
19	SGLT2 Inhibitors May Predispose to Ketoacidosis The Journal of Clinical Endocrinology & Metabolism ·Simeon I. Taylor, Jenny E. Blau, Kristina I. Rother Hit paper breakdown →	2015	396
20	Possible adverse effects of SGLT2 inhibitors on bone The Lancet Diabetes & Endocrinology ·Simeon I. Taylor, Jenny E. Blau, Kristina I. Rother	2014	214

About Jenny E. Blau

Jenny E. Blau is a scholar working on Nephrology, Endocrinology, Diabetes and Metabolism, Epidemiology, Neurology and Nutrition and Dietetics, having authored 39 papers that have together received 1.5k indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (14 papers), Neuroblastoma Research and Treatments (7 papers), Parathyroid Disorders and Treatments (7 papers), Liver Disease Diagnosis and Treatment (6 papers), Lung Cancer Research Studies (5 papers), Genetic Syndromes and Imprinting (4 papers), Diet, Metabolism, and Disease (4 papers) and Diabetes Treatment and Management (4 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (989 citations), Nephrology (218 citations), Nutrition and Dietetics (230 citations), Endocrine and Autonomic Systems (85 citations) and Surgery (506 citations). Jenny E. Blau has collaborated with scholars based in United States, Sweden and United Kingdom. Frequent co-authors include Kristina I. Rother, Simeon I. Taylor, Michael T. Collins, Sri Harsha Tella, Allison C. Sylvetsky, Mary Walter, Viviana Bauman, Amber L. Beitelshees, Rebecca J. Brown and Peter J. Walter. Their work appears in journals such as The Journal of Clinical Endocrinology & Metabolism, Diabetes/Metabolism Research and Reviews, The Lancet Diabetes & Endocrinology, Reviews in Endocrine and Metabolic Disorders and JCI Insight.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact